The aim of this study was to review our experience and demonstrate the safety of intracavitary brachytherapy (ICB) in patients with nasopharyngeal carcinoma (NPC).

Methods.

Hundred seventy-eight patients with early T1-2b disease underwent radical external beam radiation therapy (EBRT) followed by ICB boost. The primary tumor received 66 Gy of EBRT over 33 fractions using 6 or 10 MV photons. ICB insertions were performed 1 week later, delivering 10 Gy in 2 fractions over 8 days. Kaplan-Meier survival analyses were used to calculate the actuarial 5-year overall survival (OS), cause-specific survival, local control, and disease-free survival (DFS).

Results.

Five-year local control rates were 91.6%. OS, DFS, and cause-specific survival were estimated to be 85.25%, 81.7%, and 87.9%, respectively. Median follow-up was 86 months. There were no documented serious complications noted with ICB.

Conclusion.

REFERENCES

1 Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell J. Cancer incidence in five continents. Vol VI. IARC Scientific Publication. Lyon: IARC; 1992. p 6(120).
Google Scholar
2 National Cancer Control Office, Nanjing Institute of Geography. Atlas of cancer in the People's Republic of China. Shanghai: China Map Press; 1980.
Google Scholar
3 A Seow, WP Koh, KS Chia, LM Shi, Lee HP, Shanmugaratnam K. Trends in cancer incidence in Singapore, 1968 to 2002. In Singapore Cancer Registry Report No. 6. Singapore Cancer Registry, http://www.hpb.gov.sg/data/hpb.home/files/edu/report_1968_2002.pdf 2004. pp 88–89.
Google Scholar
4 Fong KW, Chua EJ, Chua ET, et al. Patient profile and survival in 270 computer tomography staged patients with nasopharyngeal cancer treated at the Singapore General Hospital. Ann Acad Med Singapore; 25: 341–346.
CAS PubMed Google Scholar
5 Amornmarn R, Prempree T, Sewchand W, et al. Radiation management of advanced nasopharyngeal cancer. Cancer 1983; 52: 802–807.
10.1002/1097-0142(19830901)52:5<802::AID-CNCR2820520509>3.0.CO;2-M
CAS PubMed Web of Science® Google Scholar
6 Chang JTC, See LC, Tang SG, et al. The role of brachytherapy in early-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1996; 36: 1019–1024.
10.1016/S0360-3016(96)00416-6
CAS PubMed Web of Science® Google Scholar
7 Choy D, Sham JST, Wei WI, et al. Transpalatal insertion of radioactive gold grain for the treatment of persistent and recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1993; 25: 505–512.
10.1016/0360-3016(93)90073-5
CAS PubMed Web of Science® Google Scholar
8 Lee AWM, Poon YF, Foo W, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976–1985: overall survival and patterns of failure. Int J Radiol Oncol Biol Phys 1992; 23: 261–270.
10.1016/0360-3016(92)90740-9
CAS PubMed Web of Science® Google Scholar
9 Lin ZX, Li DR. Preliminary experience of HDR brachytherapy for nasopharyngeal carcinoma. Abstract of the 8th International Brachytherapy Conference, Nice, France, Nov. 25–28, 1995.
Google Scholar
10 Levendag PC, Schmitz PI, Jansen PP, et al. Fractionated high-dose-rate brachytherapy in primary carcinoma of the nasopharynx. J Clin Oncol 1998; 16: 2213–2220.
10.1200/JCO.1998.16.6.2213
CAS PubMed Web of Science® Google Scholar
11 Teo PML, Kwan WH, Yu P, et al. A retrospective study of the role of intracavitary brachytherapy and the prognosticators determining local tumor control after primary radical radiotherapy in 903 non-disseminated nasopharyngeal carcinoma. Clin Oncol 1996; 8: 160–166.
10.1016/S0936-6555(96)80040-9
CAS PubMed Google Scholar
12 Vikram B, Mishra UB, Strong EW, et al. Patterns of failure in carcinoma of the nasopharynx. I. Failure at the primary site. Int J Radiat Oncol Biol Phys 1985; 11: 1455–1459.
10.1016/0360-3016(85)90332-3
CAS PubMed Web of Science® Google Scholar
13 Wang CC. Improved local control of nasopharyngeal carcinoma after intracavitary brachytherapy boost. Am J Clin Oncol 1991; 14: 5–8.
10.1097/00000421-199102000-00002
CAS PubMed Web of Science® Google Scholar
14 Yamashita S, Kondo M, Inuyama Y, et al. Improved survival of patients with nasopharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 1986; 12: 307–312.
10.1016/0360-3016(86)90343-3
CAS PubMed Web of Science® Google Scholar
15 Zhang YW, Liu TF, Fi CX. Intracavitary radiation treatment of nasopharyngeal carcinoma by high dose rate afterloading technique. Int J Radiat Oncol Biol Phys 1989; 16: 315–318.
10.1016/0360-3016(89)90321-0
CAS PubMed Web of Science® Google Scholar
16 Chong VFH, Tsao SY. Nasopharyngeal carcinoma. Singapore: Armour Publishing; 1997. pp 90–102.
Web of Science® Google Scholar
17 Yan JH, Qin DX, Hu YH, et al. Management of local residual primary lesion of nasopharyngeal carcinoma: are higher doses beneficial? Int J Radiat Oncol Biol Phys 1989; 16: 1466–1469.
10.1016/0360-3016(89)90950-4
Google Scholar
18 Lee AWM, Law SC, Foo W, et al. Nasopharyngeal carcinoma: local control by megavoltage irradiation. Br J Radiol 1993; 66: 529–536.
10.1259/0007-1285-66-786-528
Google Scholar
19 Marks JE, Bedwinek JM, Lee F, et al. Dose response analysis for nasopharyngeal carcinoma. Cancer 1982; 50: 1042–1050.
10.1002/1097-0142(19820915)50:6<1042::AID-CNCR2820500604>3.0.CO;2-Y
CAS PubMed Web of Science® Google Scholar
20 Teo PML, Leung SF, Fowler J, et al. Improved local control of early T-stage nasopharyngeal carcinoma—a tale of two hospitals. Radiother Oncol 2000; 57: 155–166.
10.1016/S0167-8140(00)00248-6
CAS PubMed Web of Science® Google Scholar
21 Levandag PC, Lagerwaard FJ, de Pan C, et al. High-dose, high-precision options for boosting cancer of the nasopharynx. Radiother Oncol 2002; 63: 67–74.
10.1016/S0167-8140(02)00008-7
PubMed Web of Science® Google Scholar
22 Leung TW, Tung SY, Sze WK, et al. Treatment results of 1070 patients with nasopharyngeal carcinoma: an analysis of survival and failure patterns. Head Neck 2005; 27: 555–565.
10.1002/hed.20189
CAS PubMed Web of Science® Google Scholar
23 Lee N, Hoffman R, Phillips TL, et al. Managing nasopharyngeal carcinoma with intracavitary brachytherapy: one institution's 45-year experience. Brachytherapy 2002; 1: 74–82.
10.1016/S1538-4721(02)00013-2
PubMed Google Scholar
24 Syed AMN, Puthawala AA, Damore SJ, et al. Brachytherapy for primary and recurrent nasopharyngeal carcinoma: 20 years' experience at Long Beach Memorial. Int J Radiat Oncol Biol Phys 2000; 47: 1311–1321.
10.1016/S0360-3016(00)00520-4
CAS PubMed Web of Science® Google Scholar
25 Leung TW, Wong VYW, Sze W-K, et al. High dose rate intracavitary brachytherapy boost for early T stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2008; 70: 361–367.
10.1016/j.ijrobp.2007.06.078
PubMed Web of Science® Google Scholar
26 Lee N, Xia P, Quivey JM, et al. Intensity modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 2002; 53: 12–22.
10.1016/S0360-3016(02)02724-4
PubMed Web of Science® Google Scholar
27 Kam MKM, Teo PML, Chau RMC, et al. Treatment of nasopharyngeal carcinoma with intensity modulated radiotherapy: the Hong Kong experience. Int J Radiat Oncol Biol Phys 2004; 60: 1440–1450.
10.1016/j.ijrobp.2004.05.022
PubMed Web of Science® Google Scholar

Citing Literature

Volume31, Issue12

December 2009

Pages 1610-1618

Brachytherapy boost for T1/T2 nasopharyngeal carcinoma

Abstract

Background.

Methods.

Results.

Conclusion.

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Brachytherapy boost for T1/T2 nasopharyngeal carcinoma

Abstract

Background.

Methods.

Results.

Conclusion.

REFERENCES

Citing Literature

References

Related

Information